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Hydroxyurea (HU), the first of two drugs approved by the US Foodand Drug Administration for treating patients with sickle cell dis-ease (SCD), produces anti-sickling effect by re-activating fetal 
γ-globin gene to enhance production of fetal hemoglobin. However,
approximately 30% of the patients do not respond to HU therapy. The
molecular basis of non-responsiveness to HU is not clearly understood.
To address this question, we examined HU-induced changes in the RNA
and protein levels of transcription factors NF-Y, GATA-1, -2, BCL11A,
TR4, MYB and NF-E4 that assemble the γ-globin promoter complex and
regulate transcription of γ-globin gene. In erythroblasts cultured from
peripheral blood CD34+ cells of patients with SCD, we found that 
HU-induced changes in the protein but not the RNA levels of activator
GATA-2 and repressors GATA-1, BCL11A and TR4 correlated with 
HU-induced changes in fetal hemoglobin (HbF) levels in the peripheral
blood of HU high and low responders. However, HU did not significant-
ly induce changes in the protein or RNA levels of activators NF-Y and
NF-E4. Based on HU-induced changes in the protein levels of GATA-2, -
1 and BCL11A, we calculated an Index of Hydroxyurea Responsiveness
(IndexHU-3). Compared to the HU-induced fold changes in the individ-
ual transcription factor protein levels, the numerical values of IndexHU-
3 statistically correlated best with the HU-induced peripheral blood HbF
levels of the patients. Thus, IndexHU-3 can serve as an appropriate indi-
cator for inherent HU responsiveness of patients with SCD. 
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ABSTRACT
Introduction
Sickle cell disease (SCD) is a common, genetic disorder of adult b-hemoglobin,
which affects millions of people of diverse racial groups worldwide, including
approximately 100,000 Americans, mostly of African descent. Hydroxyurea (HU)
is the first of two US Food & Drug Administration (FDA)-approved drugs for treat-
ing SCD. In contrast to the recently approved Endari (L-glutamine), HU is shown
to ameliorate the SCD symptoms by re-activating the fetal γ-globin gene to pro-
duce fetal hemoglobin (HbF) with anti-sickling activity,1-10 although HU also pro-
vides beneficial effects in decreasing adhesion of sickle erythrocytes to vascular
endothelial cells, thus reducing complications of vaso-occlusion and infarction.11,12
However, approximately  30% of SCD patients do not respond to HU therapy in
increasing HbF levels to ameliorate the SCD symptoms.3-10
The molecular basis of HU non-responsiveness is largely
unknown. 
The fetal γ-globin gene is silenced in adult erythroid cells
but can be re-activated through mechanisms that include
the signal-transduction pathway.13 Thus, the cGMP path-
way provides a potential mechanism of γ-globin gene re-
activation by HU: HU and/or the nitric oxide generated by
HU binds to and activates soluble guanylyl cyclase to syn-
thesize cGMP;14,15 cGMP in turn activates cGMP-depen-
dent protein kinase PKG to phosphorylate and activate
p38 MAPK,16,17 whose downstream targets ultimately
impinge on the γ-globin promoter to activate synthesis of
γ-globin mRNA and HbF to produce anti-sickling effect.13,18
However, the nuclear targets of the HU-induced signaling
pathway, the transcription factors (TFs) that bind to γ-glo-
bin promoter and activate transcription of  γ-globin gene,
have not been clearly identified. 
A number of TFs bind to the proximal γ-globin promot-
er and regulate transcription of γ-globin gene. These TFs
could be the ultimate nuclear targets of HU in re-activating
γ-globin gene in adult erythroid cells. For example, NF-Y
binds to the tandem CCAAT motifs in the γ-globin pro-
moter to serve as a pioneering TF in recruiting other TFs
to assemble the proximal γ-globin promoter complex and
activate transcription of γ-globin gene (Figure 1).19-21
CoupTFII and dimeric TR2/TR4 compete with NF-Y for
binding to DNA motifs overlapping the distal CCAAT box
and repress γ-globin gene;22-25 GATA-1, and -2 bind to the
GATA motif in γ-globin proximal promoter to respectively
repress and activate γ-globin gene21,26,27 NF-E4/CP2 dimer
binds to its cognate DNA motif near the TATA box to acti-
vate γ-globin gene28 (Figure 1). In addition, BCL11A and
MYB are involved in γ-globin gene regulation, since their
genetic variants are associated with elevation of HbF lev-
els.29,30 BCL11A can bind to DNA motifs distal to the 
γ-globin promoter and act over distance to indirectly
repress transcription of γ-globin gene,31,32 although
BCL11A as well as MYB also binds directly to the γ-globin
promoter to repress γ-globin gene (Figure 1).21,33,34 Thus, the
inactive γ-globin promoter in adult erythroid cells  can
bind both a repressor hub of BCL11A/GATA-
1/CoupTFII/TR2/TR4 and an activator hub of NF-
Y/GATA-2/NF-E4 (Figure 1).21 The poised state of the 
γ-globin promoter suggests that pharmacological com-
pounds including HU can modulate the levels of the TFs
in the activator and repressor hubs to re-activate the
silenced γ-globin gene in adult erythroid cells.
Here, we report that, in erythroblasts cultured ex vivo for
ten days from peripheral blood CD34+ cells of HU high
responsive SCD patients, HU increased the protein level
of activator GATA-2 and drastically decreased the protein
levels of repressors GATA-1, BCL11A, TR4 and MYB to
activate transcription of γ-globin gene and synthesis of
HbF to produce corresponding anti-sickling effect. In cul-
tured erythroblasts of HU low/non-responders, such HU-
induced differential changes in protein levels of the key
activator and repressors were not observed. Our findings
indicated that HU-induced changes in protein levels, but
not RNA levels, of key TFs in the γ-globin promoter com-
plex were strong modulators of HU responsiveness of the
SCD patients. Thus, IndexHU-3, based on combined, HU-
induced changes in protein levels of GATA-2, -1 and
BCL11A, could serve as a strong indicator for inherent HU
responsiveness of the SCD patients. 
Methods
Isolation of CD34+ cells from peripheral blood 
samples and ex vivo culture of CD34+ cells 
in the presence or absence of HU
CD34+ cells were isolated from peripheral blood (30 mL) of
homozygous HbS/HbS SCD patients seen at the pediatric and
adult sickle cell clinics at Medical College of Georgia (MCG),
Augusta University, USA and from aphoresed mononuclear cells
of normal donors obtained anonymously from MCG Tumor Cell
Bank, using protocol approved by the institutional review board
(HAC #1009064). The isolated CD34+ cells were cultured to days
10-12 in appropriate medium as described,21,35 in the absence or
presence of 50 µM HU, which was the lowest concentration of
HU that activated γ-globin mRNA to a high level (see Online
Supplementary Methods and Online Supplementary Figure  S1). 
RNA and protein analyses by qRT-PCR, RNA-seq 
and Western blots 
The numerical values of HU-induced fold changes, the +HU/-
HU values, in the RNA and protein of each TF were calculated as
the ratios of the levels of the RNA or protein normalized to the
RNA and protein levels of b-actin in cells cultured with HU over
the normalized levels of the respective RNA and protein in cells
cultured without HU (Online Supplementary Methods). 
Calculation of IndexHU
IndexHU-3 was calculated according to the formula: IndexHU-
3= (FcGATA-2)/(FcGATA-1)x(FcBCL11A), where Fc was the fold
change of the respective TFs induced by HU, i.e. the +HU/-HU
ratio obtained as shown above. IndexHU-4 was calculated with
(FcTR4) included in the denominator and IndexHU-5 with both
(FcTR4) and (FcMYB) included in the denominator. 
Statistical analysis
Correlation between HU-induced changes in RNA and protein
levels of the TFs and HU-induced HbF levels was performed using
Prism 5 linear regression analysis program. Pearson correlation
coefficient was calculated between peripheral blood HbF levels
and IndexHUs. A 2-sample t-test was performed to compare HU-
induced changes in each of the TFs and to compare the IndexHUs
between high- and low/non-responders. Paired t-test was used to
analyze equivalence of HU-induced changes in HbF levels in cul-
tured erythroblasts and in peripheral blood of the SCD patients.
The statistical tests were two-sided at 0.05 significance levels with
SAS 9.4.0 (SAS InstituteInc., Cary, NC, USA).
Hypoxia condition to induce sickling of SCD 
erythrocytes
Day 12 erythrocytes were isolated from ex vivo cultured day 12
cells (erythroblasts mixed with erythrocytes) of peripheral blood
CD34+ cells by Ficoll-Paque gradient as described (Online
Supplementary Methods). The day 12 erythrocytes were deoxy-
genated in a hypoxia chamber (Coy Laboratory Products) at 2%
oxygen for 6 hours. The deoxygenated cells were fixed with 3.7%
formaldehyde on ice for 15 minutes in the hypoxia chamber
before removal to atmosphere for microscopic observation and
imaging (EVOS fluorescent cell imaging system). 
Results
HU increased HbF levels and produced anti-sickling
effect in ex vivo cultured erythroid cells
In order to unambiguously analyze the molecular basis
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of HU-responsiveness of SCD patients, we focused on
two groups of patients with widely separated peripheral
blood HbF levels induced by HU therapy: the HU
low/non-responsive patients with post HU HbF levels of
≤10% and the HU high responsive patients with post HU
HbF levels of 20-30%3,9 (Online Supplementary Table S1).
We isolated CD34+ cells from peripheral blood samples of
the SCD patients and cultured the CD34+ cells in erythroid
differentiation medium for ten days in the presence or
absence of HU. To validate these ex vivo cultured day 10
erythroblasts as an appropriate cell system for dissecting
the molecular basis of HU responsiveness, we compared
the HbF levels induced by HU in cultured day 10 erythrob-
lasts and in peripheral blood of the SCD patients. We
found that in day 10 erythroblasts of HU high responders
SCD 01 and 02 and low responder SCD 04, HU increased
HbF levels by 2.5-, 2.1- and 2-fold, from 8% to 20%, 14%
to 29% and 4% to 8%, respectively (Figure 2A). In the
peripheral blood of these 3 SCD patients, the clinical
records showed that HU at maximum tolerated dose
(MTD) increased HbF levels by 2.1-, 2.7- and 2-fold, from
12% to 25%, 11% to 30% and 3% to 6%, respectively
(Table 1 and Online Supplementary  Table S1). The compa-
rable fold changes in HbF levels induced by HU in cultured
erythroblasts and in initial HU trials at maximum tolerat-
ed dose (MTD) in peripheral blood of both HU responsive
and low/non-responsive SCD patients (see Online
Supplementary  Table S2 for paired t-tests) indicated that
successive transfusions in SCD04 and other low/non-
responsive patients on blood exchange (Online
Supplementary  Table S1), which could blunt subsequent
HbF induction by HU in the patients, did not exert lasting
genetic effects on patient CD34+ cells to suppress HU-
induced HbF levels in cultured day 10 erythroblasts. Thus,
the ex vivo cultured patient erythroblasts could serve as an
appropriate cell system for designing bioassays to dissect
the in vivo molecular basis of HU responsiveness of the
SCD patients. 
Since the HU low responsive SCD04 patient required
blood exchange from normal donors to ameliorate the
SCD symptoms, HbA expressed by donor erythrocytes, in
addition to patient HbS, was detected by HPLC in the
exchanged peripheral blood of the patient (Figure 2A, right
2nd panel). However, the donor HbA was not detected by
HPLC in the cultured day 10 erythroblasts (Figure 2A,
right 3rd and 4th panels). This was expected, since the trans-
fused, donor blood did not contain nucleated progenitor
cells including CD34+ cells, which were removed prior to
transfusion. Thus, the day 10 erythroblasts were derived
only from the patient CD34+ cells and expressed only
HbS. In HPLC analysis of HbF levels in patient erythro-
cytes after blood exchange, HbF% was calculated as
HbF/HbF+HbS without including HbA (see Online
Supplementary Methods), since HbA was expressed in sepa-
rate donor erythrocytes. However, the calculated HbF%
of 6% for SCD04 (Figure 2A, right 2nd panel) could be over-
estimated slightly, since the HbF peak in HPLC contained
also approximately 0.2-0.5% of HbF contributed by the
normal donor erythrocytes (Table 1). 
Hypoxia chamber assay of cultured day 12 erythrocytes
showed that HU treatment reduced sickled erythrocytes
of HU high responder, SCD 02, from 38% to 20%, and
HU low responder, SCD 04, from 80% to 58% (Figure 2B).
Thus, HU-induced increase in HbF levels correlated with
Hydroxyurea on protein levels of transcription factors 
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Figure 1. Molecular assembly of the key transcription factors (TFs) in proximal γ-globin promoter complex. (A)  Sequence of the proximal γ-globin promoter.
Underlined bases: DNA motifs that bind transcription factors as marked. Numbers in parentheses: first base positions in the motifs relative to the transcription start
site of γ-globin mRNA at +1 located 25 bases 3’ of the TATA box. The MYB binding site CAATG at -18133 was not shown. (B)  Proximal γ-globin promoter complex. Blue
ribbon: promoter DNA containing transcription activator-binding motifs (red bars) and repressor-binding motifs (light green bars), which respectively bind transcription
activators, NF-Y, GATA-2 and NF-E4, marked in red and transcription repressors, BCL11A, GATA-1, CoupTFII and TR2/TR4, marked in green. Blue rectangle with angled
arrow: γ-globin gene and transcriptional direction of γ-globin mRNA. NF-Y, composed of subunits YA, YB and YC, binds to each of the tandem CCAAT motifs and bends
the DNA by approximately 70° to form the pocket to recruit and interact with other TFs in assembling the proximal promoter complex (adapted from Zhu et al.21).
MYB protein was not shown, as its interaction with TF partner(s) in the proximal γ-globin promoter complex was not known. 
A
B
HU-induced reduction in sickling of the erythrocytes
(Figure 2C). The cell sickling assays together with the
HPLC analysis (Figure 2A) showed that cultured patient
erythroblasts provided an appropriate ex vivo cell system
for dissecting the molecular basis of HU-responsiveness of
the SCD patients. 
HU slowed down the cell cycle but did not delay 
ex vivo erythropoiesis of cultured patient erythroblasts
As HU is an inhibitor of DNA synthesis,37 it could slow
down cell division and delay ex vivo erythropoiesis.2,38
Thus, it could be argued that the HU treated day 10 ery-
throblasts, as compared to the untreated day 10 erythrob-
lasts, contained more abundant earlier stage erythroblasts,
which expressed higher levels of γ-globin gene and thus
higher HbF levels. Therefore, HU-induced HbF production
did not directly involve TF-mediated nuclear events on
transcription of the γ-globin gene. 
To investigate this possibility, we analyzed by FACS the
day 10 cells stained with antibodies against erythroid dif-
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Figure 2. Hydroxyurea (HU) increased fetal hemoglobin (HbF) levels and produced anti-sickling effect in cultured erythrocytes of sickle cell disease (SCD) patients.
(A) HPLC analysis of HbF levels in day 10 erythroblasts (Day 10E) and HbFPB in peripheral blood (P.blood) of SCD patients. (-HU) and (+HU): day 10 erythroblasts cul-
tured without and with HU, or patient peripheral blood obtained before HU therapy and after HU and blood exchange (Bex) therapies. HbF, HbS and HbA elution
peaks were as marked. y-axis: absorption units (AU) at 410 nm of the eluted hemoglobins; x-axis: time in minutes when the hemoglobins were eluted from the HPLC
column. (B) Day 12 erythrocytes (Day 12e) of HU high and low responders, SCD02 and 04, respectively, cultured without and with HU, and subjected to hypoxia to
induce cell sickling. Images of peripheral blood erythrocytes of SCD04 without and with HU therapy were similar to those of cultured erythroblasts (data not shown).
(C) Percentages of sickled erythrocytes [among 400 counted cells in images in  (2B)] plotted against HU-induced HbF levels of Day 10 erythroblasts from the same
patients in (2A). (D) FACS analysis of Day 10 erythroblasts cultured without and with HU from HU high responders SCD 01, 02, and low responders SCD04, 14. Cells
were stained with erythroid markers CD71 and CD235a, respectively.  
A
D
B
C
ferentiation markers transferrin receptor and
glycophorinA to determine if HU-treated day 10 cells con-
tained more abundant early stage erythroblasts. We found
that day 10 cells cultured in the presence or absence of HU
showed similar staining patterns for both HU high and
low responders (Figure 2D and Online Supplementary
Figure S2), indicating that the HU-treated erythroblasts did
not contain a higher proportion of earlier erythroid pro-
genitors. However, the cell numbers of the day 10 ery-
throblasts grown in the presence of HU were 1/2 to 1/4 of
those grown in the absence of HU for both HU high and
low responsive patients. This indicated that HU slowed
down the cell culture by 1-2 cell divisions without appar-
ently delaying the ex vivo erythropoiesis of the day 10 ery-
Hydroxyurea on protein levels of transcription factors 
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Table 1. Hydroxyurea (HU)-induced changes in RNA and protein levels of transcription factors (TFs), γ-globin (γ-glob) and fetal hemoglobin (HbF)
levels in day 10 erythroblasts of 18 sickle cell disease (SCD) patients (SCD #1-18) and 3 normal donors (Normal #1-3).  
SCD NFY GATA2 GATA1 BCL TR4 MYB NFE4 γ-glob HbF% HbF%PB IndexHU-3
1   RNAa 4.7 1.3 0.9 2.8
Protein 2.86 0.195 0.175 3.51 8/20 12/25 83.8
2   RNAa 4.4 0.9 0.83 2.5
RNAb 0.93 4.1 0.97 0.65 0.8 1.38 2.09 14/29 11/30 101.6
Protein 2.9 0.172 0.166
8   RNAa 1.1 3.7 0.97 0.86 0.87 0.57 0.95 2.0
RNAb 1.11 2.47 1.04 0.75 1.03 0.44 2.44
Protein 0.93 1.21 0.25 0.10 0.23 0.29 0.90 1.81 5.3/16.4 6.2/17 42
9   RNAa 1.13 3.88 1.38 0.61 0.5 0.53 1.1 2.38
Protein 1.11 1.42 0.18 0.08 0.14 0.09 1.17 2.94 6/18 7/22 98.6
10  RNAa 0.99 2.67 0.89 0.78 0.87 0.61 0.95 2.53
Protein 1.10 1.74 0.21 0.10 0.18 0.2 0.82 3.86 12/23.6 83
3    RNAa 4.1 1.2 1.2 1.8
Protein 0.99 0.53 0.61 4.2/9 4.5/8.8 3.0
4    RNAa 2.9 1.2 1.1 1.25
Protein 1.9 0.53 0.49 4/8 3/6 7.3
5    RNAa 2.7 0.7 0.8 1.2
Protein 2.24 3.2 0.34 2.2/5.3 1.5/4.9 2.1
6    RNAa 0.94 2.5 0.89 0.78 0.83 0.63 1.0 1.87
Protein 0.95 1.0 0.52 0.68 1.16 0.2 0.93 1.23 4/10 2.8
7    RNAa 0.95 1.96 1.0 0.95 0.96 1.1 0.99 1.51
Protein 1.12 1.05 0.78 0.58 0.95 1.0 0.98 1.06 5.1/9.6 4.7/11.5 2.3
11  RNAa 3.25 1.2 0.7 1.75
Protein 0.87 0.95 0.99 3/4 3.2/3.1 0.9
12  RNAa 3.49 1.21 0.72 1.63
Protein 0.76 0.4 0.4 1.2/2.9 4.7
13  RNAa 4.8 1.16 0.5 0.46
Protein 0.42 0.48 0.65 2.1/3.5 1.4
14  RNAa 3.39 0.61 0.66 0.53
RNAb 0.86 2.64 0.57 0.4 0.98 0.85 0.51
Protein 0.54 0.77 1.17 1.1/1.8 0.6
Normal NFY GATA2 GATA1 BCL TR4 MYB NFE4 γ-glob HbF% HbF%PB IndexHU-3
15  RNAa 2.78 1.06 0.79 1.12
Protein 0.67 0.41 0.95 1.4/2.9 1.7
16  RNAa 3.79 0.74 0.82 1.16
Protein 1.7 0.93 0.64 2.6/3.8 2.9
17  RNAa 1.10 1.87 1.38 0.87 1.10 1.27
Protein 1.05 1.06 1.04 1.13 0.95 0.7/1.0 0.9
18  RNAa 0.97 1.53 0.82 0.9 0.75 0.58 1.36
RNAb 1.05 2.56 0.96 0.98 0.63 0.7 1.89
Protein 1.14 0.91 0.78 1.47 0.86 0.49 1.16 2.1/3.7 0.8
Normal
1    RNAa 0.98 1.91 0.98 1.13 0.91 0.75 1.41
Protein 1.0 1.65 1.0 1.23 0.24 0.39 1.28 0.2 1.3
2    RNAa 1.79 0.86 1.34 1.1
Protein 1.1 1.07 1.06 0.3 1.0
3    RNAa 1.63 0.9 0.65
Protein 1.6 0.91 0.62 0.5 5.5
RNAa and RNAb: hydroxyurea (HU)-induced changes in RNA levels in total cellular RNAs determined by qRT-PCR and RNA-seq, respectively. Protein: HU-induced changes in pro-
tein levels determined by Western blots. Numbers: HU-induced fold changes, +HU/-HU, in RNAs and proteins. HbF%PB : fetal hemoglobin (HbF) levels in peripheral blood (PB)
of the sickle cell disease (SCD) patients; two numbers separated by a slash: HbF levels in day 10 erythroblasts before and after HU treatment or HbF levels in peripheral blood
of SCD patients pre- and post-HU treatment at maximum tolerated dose (MTD)  recorded in the clinic. IndexHU-3: quantitative estimates of HU responsiveness calculated from
HU-induced changes in the protein levels of GATA2, GATA-1 and BCL11A. CoupTFII was not analyzed as its RNA was not detected by RNA-seq on day 10 erythroblasts cultured
either with or without HU (Online Supplementary File 2), nor was TR2, as TR4 with lower RNA level than TR2 RNA level (Online Supplementary File 2) appeared to be the limiting
partner in the TR2/TR4 heterodimer.  See Online Supplementary Files S1 and S2 for data and calculations.
throblasts. One explanation could be that, in our cell cul-
ture condition, HU was added on day 4, by which time
the erythroid differentiation program of the cultured cells
could have already been set up. Therefore, HU did not
appreciably delay the differentiation of the cultured ery-
throblasts, indicating that the cultured erythroblasts were
appropriate for subsequent studies to dissect the molecu-
lar basis of HU responsiveness of the SCD patients.
HU-induced changes in protein but not RNA levels of
key TFs correlated with HU-induced HbF levels in 
cultured erythroblasts of SCD patients
To determine the HU-induced changes in the RNA and
protein levels of activators NF-Y, GATA-2 and NF-E4 and
repressors GATA-1, BCL11A, TR4 and MYB that assemble
the γ-globin proximal promoter complex (Figure 1), we
used qRT-PCR, RNA-seq and Western blots to analyze the
day 10 erythroblasts cultured with or without HU. To
achieve statistical significance for the bioassays, we ana-
lyzed a total of 18 homozygous SCD patients (7 pediatric
and 11 adult patients) among whom 5 were HU high
responders (SCD 01, 02, 08, 09 and 10) and 13 were HU
low responders (Online Supplementary Table S1). Although
HU low/non-responsive patients comprise approximately
30% of the SCD patients, approximately 70% of the
blood samples examined in this study were from
low/non-responsive patients, because blood samples in
large volumes of 30 mL required for the bioassays were
more readily available from HU low/non-responsive
patients undergoing blood exchange (see Online
Supplementary Methods).
RNA analysis by qRT-PCR was performed for all 18
SCD patients and 3 normal donors; genome-wide RNA-
seq analysis was performed for HU high responders (SCD
02 and 8), and HU low responders (SCD 14 and 18). The
results showed that HU significantly and universally
increased GATA-2 RNA levels by 200-500% in day 10 ery-
throblasts of both HU high and low responders and the
normal donors (Table 1, Figure 3A, and Online
Supplementary Files 1 and 2), in agreement with an earlier
report.39 In contrast, HU mildly decreased or increased by
≤50% the RNA levels of repressors GATA-1, BCL11A,
TR4 and MYB in erythroblasts of all the SCD patients and
normal donors (Table 1 and Online Supplementary Files 1
and 2). These results were consistent with earlier reports
that HU treatment modulates the RNA levels of BCL11A
and MYB.40,41 However, CoupTFII RNA was not detected
by either RT-PCR or RNA-seq (Online Supplementary File 2)
in day 10 erythroblasts and was not further analyzed.
The HU-induced changes in TF RNA levels did not con-
sistently correspond to HU-induced changes in protein
levels of the respective TFs. Thus, despite the HU-
induced, universal increase in GATA-2 RNA levels in all
SCD patient erythroblasts, HU increased GATA-2 protein
level only in HU high responders SCD 01, 02, 08-10,
whereas HU appeared to randomly decrease or increase
GATA-2 protein level in the HU low responders (Table 1
and Figure 3B). Similarly, despite the HU-induced mild
changes in RNA levels of repressors GATA-1, BCL11A,
TR4 and MYB in the 18 SCD patient erythroblasts, HU
drastically decreased by 70-80% the protein levels of these
repressors only in high responders SCD 01, 02, 08, 09 and
10; but HU did not reduce or mildly reduced by ≤50% the
repressor protein levels in the erythroblasts of HU
low/non-responders SCD 03-7  and  11-18, with the
exception that MYB protein level was significantly
reduced by ≥50% also in HU low responders SCD 06 and
18 (Table 1 and Online  Supplementary File S1). Statistical
analysis by 2-sample t-tests confirmed that HU differen-
tially modulated the protein levels, but not the RNA lev-
els, of the repressors in HU high versus HU low respon-
ders; in contrast, in both HU high and low responders, HU
did not induce significant changes in either the protein or
the RNA levels of NF-Y and NF-E4, indicating that these
two activator TFs did not mediate HU responsiveness of
the SCD patients (Online Supplementary Table S3). 
In HU high responders, HU drastically decreased the
repressor protein levels and mildly increased the protein
level of activator GATA-2, which in combination lead to
activation of γ-globin RNA transcription, synthesis of 
γ-globin protein and HbF (Table 1,  and  Online
Supplementary Table S3 and Online Supplementary Figure
S3A), and consequently production of anti-sickling effect
in both the cultured erythroblasts and peripheral blood of
the SCD patients (Figure 2B and C). In HU low respon-
ders, HU mildly decreased the repressor protein levels and
inconsistently increased GATA-2 protein level, which in
combination did not sufficiently activate γ-globin gene
and synthesis of HbF to produce significant anti-sickling
effect in these patients.
We next used scatter plots to statistically and graphically
correlate the HU-induced changes in protein and RNA lev-
els of the TFs with HU-induced changes in HbF levels in
peripheral blood of the 18 SCD patients. Regression analy-
sis showed that HU-induced changes in GATA-1 and
BCL11A protein levels, but not RNA levels, significantly
correlated with HU-induced changes in peripheral blood
HbF levels of the patients, while the correlation between
GATA-2 protein levels and HbF levels was less significant
(Figure 4A and B). The negative slopes of the correlation
graphs of GATA-1 and BCL11A (higher HU-induced
repressor protein levels correlating with lower HU-
induced HbF levels) were consistent with GATA-1 and
BCL11A being repressors of γ-globin gene; the positive
slope of the GATA-2 graph was consistent with GATA-2
being an activator of γ-globin gene. Scatter plots also indi-
cated that the HU-induced changes in TR4 and MYB pro-
tein levels correlated less strongly with the HU-induced
changes in HbF levels, as compared to HU-induced
changes in GATA-1 and BCL11A protein levels (compare
Online Supplementary Figure S3B and C with F and G). In
contrast, HU-induced changes in GATA-2 protein level
correlated weakly but NF-Y and NF-E4 protein levels cor-
related not at all with the HU-induced changes in HbF lev-
els (Online Supplementary Figure S3D and E). Thus, the pro-
tein levels of repressors GATA-1 and BCL11A were strong
modulators and the protein level of activator GATA-2 was
a weak modulator of the HU responsiveness of the SCD
patients. 
Index of HU responsiveness, IndexHU-3, calculated
from HU-induced changes in protein levels of GATA -1,
BCL11A and GATA-2, as a numerical indicator for HU
responsiveness of SCD patients
To quantify the cumulative effects of HU-induced
changes in the protein levels of the transcription activator
and repressors, we calculated the IndexHU-3 according to
the formula: IndexHU-3= (FcGATA-2)/(FcGATA-
1)x(FcBCL11A), where Fc was the HU-induced fold
changes in the protein levels of GATA-1, -2 and BCL11A
X. Zhu et al.
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(see Methods section). The underlying rationale for the for-
mulation was that HU-induced changes in activator pro-
tein level in the numerator together with HU-induced
decrease in the repressor protein levels in the denominator
would produce numerical values of IndexHUs quantita-
tively correlating with HU-induced changes in HbF levels
and thus HU responsiveness of the SCD patients. Indeed,
IndexHU-3s had numerical values of 40-100 for HU high
responders and ≤10 for HU low/non-responders (Table 1).
Correlation analysis by scatter plots showed that
IndexHU-3 calculated from HU-induced protein levels,
but not RNA levels, correlated strongly with the HU-
induced HbF levels in peripheral blood of the SCD
patients, with R2=0.9, as compared to the correlation
between HU-induced changes in the protein levels of the
individual TFs, with R2=0.3-0.6 (Figure 4B and C). Thus,
IndexHU-3 could serve as a quantitative indicator/predic-
tor for the inherent HU responsiveness or non-responsive-
ness of the SCD patients (Online Supplementary Table S3). 
As HU also induced a drastic reduction in the protein
levels of TR4 and MYB in HU high responders, we calcu-
lated IndexHU-4 and -5 to include HU-induced (FcTR4)
and (FcMYB) in the denominator. However, plotting
IndexHU-3, -4 and -5 with respect to HU high versus HU
low responders showed that IndexHU-4 and -5 did not
improve the power to distinguish between HU high and
low responders (Figure 4D). Thus, IndexHU-3 could serve
as a reliable indicator to predict HU responsiveness of the
SCD patients.
Discussion  
In this study, we investigated the molecular basis of HU
responsiveness of SCD patients to ascertain the underly-
ing mechanism(s) of why approximately 30% of SCD
patients could not respond to HU therapy in enhancing
HbF levels to produce an anti-sickling effect and to ame-
liorate the SCD symptoms. We first validated the appro-
priateness of the ex vivo cultured patient erythroblasts for
the bioassays to dissect the in vivo molecular basis of HU
responsiveness. We found that HU similarly induced HbF
Hydroxyurea on protein levels of transcription factors 
haematologica | 2017; 102(12) 2001
Figure 3. Hydroxyurea (HU)-induced changes in RNA and protein levels of GATA-2, -1 and BCL11A in day 10 erythroblasts of HU high and low/non-responsive sickle
cell disease (SCD) patients. (A) Total cellular RNAs isolated from day 10 patient erythroblasts cultured without and with HU and analyzed by qRT-PCR. For SCD 02,
04 and 14, the RT-PCR results shown were means of technical triplicates from two independent RNA preparations normalized with respect to the RNA level of b-
actin; for SCD 01, the RT-PCR results were means of technical triplicates. y-axis: the +HU/-HU ratios of normalized RNA levels of genes in cells treated with HU over
the normalized RNA levels of the same genes in control cells not treated with HU, which were set at 1. Numbers in parentheses: numerical values of +HU/-HU ratios
of each of the genes. (B) Western blots of protein levels of GATA-1, -2 and BCL11A in day 10 erythroblasts cultured without and with HU, (-) and (+), respectively, from
the same SCD patients as in (A). Numbers underneath the blots: +HU/-HU ratios of the protein levels of the TFs normalized with respect to the protein level of b-
actin in erythroblasts treated with HU over the normalized protein levels of the same TFs in control erythroblasts without HU. HbF% and HbF%PB: Fetal hemoglobin
(HbF) levels in day 10 erythroblasts determined by HPLC and in peripheral blood of the SCD patients obtained from the clinic; ND: not done; IndexHU-3: Index of HU
responsiveness calculated from HU-induced fold changes in protein levels of GATA-2, -1 and BCL11A.
A
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levels in cultured patient erythroblasts  as  in peripheral
blood of the SCD patients on HU and/or blood exchange
therapies (Table 1 and Figure 2). It has recently been
reported that, in erythroblasts cultured from peripheral
blood CD34+ cells of a group of SCD and b-thalassemia
patients who were initially not on HU therapy but were
subsequently put on prospective HU therapy, HU-induced
changes in HbF levels either before or after HU therapy
are similar.42 This finding, together with our results, indi-
cates that HU and blood exchange therapies did not exert
lasting genetic effects on bone marrow CD34+ cells of the
patients to significantly change HU-induced HbF levels in
patient erythroblasts cultured from the CD34+ cells. 
Protein and RNA analyses of the cultured patient ery-
throblasts showed that HU-induced changes in the pro-
tein levels of repressors GATA-1 and BCL11A were strong
modulators, and activator GATA-2 a weak modulator of
HU-induced HbF levels, and hence HU responsiveness of
the SCD patients. In HU low/non-responsive patients
with post-HU HbF levels ≤10%, HU did not drastically
decrease the protein levels of the repressor TFs nor consis-
tently increase the protein level of activator GATA-2
(Table 1 and Figure 3) to sufficiently activate transcription
of γ-globin RNA and synthesis of HbF to produce signifi-
cant anti-sickling effect in cultured erythroblasts and
peripheral blood  (Figure 2). Since HU-induced changes in
the RNA levels of the key TFs did not correlate at all with
HU-induced peripheral blood HbF levels (Figure 4A), HU-
induced changes in the RNA levels of the TFs could not
serve as appropriate indicators of HU responsiveness of
the SCD patients. 
IndexHU-3, calculated from combined HU-induced
changes in the protein levels of GATA-2, -1 and BCL11A,
correlated strongly (R2=0.9) with HU-induced peripheral
blood HbF levels of the patients and, therefore, could serve
as a strong indicator of HU responsiveness (Figure 4B and
C, and Online Supplementary Table S3). It has been shown
recently that HU-induced fold changes in γ-globin RNA lev-
els in cultured erythroblasts of a group of SCD and b-tha-
lassemia patients are  the best indicator so far to predict HU
responsiveness for these patients.42 Indeed, HU-induced
fold changes in γ-globin RNA levels correlated with HU-
induced γ-globin protein and HbF levels in cultured patient
erythroblasts (Figure 2 and Online Supplementary Figure S3A)
and showed a significant difference between HU respon-
sive and non-responsive patients (Online Supplementary
Table S3). However, the HU-induced fold changes in γ-glo-
bin RNA levels were in a narrow range of 1.2-1.9 for HU
low/non-responders and 2-2.8 for HU high responders
(Table 1 and Figure 3). IndexHU-3 with numerical values of
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Figure 4. Statistical correlation analysis by scatter plots of hydroxyurea (HU)-induced fold changes in RNA and protein levels of GATA-2, -1 and BCL11A and of Index
HU with respect to HU-induced changes in peripheral blood HbF levels of the 18 sickle cell disease (SCD) patients. (A and B) Scatter plots of HU-induced fold
changes in RNA and protein levels of BCL11A, GATA-1 and -2 with respect to HU-induced peripheral blood HbF levels of the 18 SCD patients. (C) Scatter plots of
IndexHU-3s calculated from HU-induced fold changes in the RNA and protein levels of GATA-2, -1 and BCL11A plotted against HU-induced peripheral blood HbF levels
of the 18 SCD patients. (D) IndexHU-3, -4 and -5 calculated from the HU-induced changes in protein levels of 3, 4 and 5 TFs in 6 SCD patients. SCD 08, 09 and 10:
HU high responders; SCD 06, 07 and 18: HU low responders. y-axis: numerical values of the respective IndexHUs; P-values: significance of the separation in the
numeric values of IndexHU-3, -4 and -5 of the HU high versus low responsive groups.  
A B C
D
40-100 for high responders and <10 for low/non-responders
(Table 1 and Figure 3),  therefore, provided a much wider
numeric range for more accurate assessment of HU respon-
siveness of the SCD patients. 
Hydroxyurea could modulate the protein levels of the
key TFs by modulating translational efficiency and/or sta-
bility of the TF proteins. Thus, genetic variations in HU
low/non-responders, such as quantitative trait loci (QTL)
identified by single nucleotide polymorphisms (SNPs) to
associate with HU response in SCD patients,43 could
impair critical steps in the HU-mediated protein transla-
tion and degradation pathways of the key TFs, resulting in
low HU responsiveness of the patients. Recent studies on
translational initiation and ribosome profiling show that
the translation efficiency of key erythroid mRNAs, includ-
ing BCL11A and γ-globin mRNAs, is dynamically con-
trolled during erythropoiesis and could be subject to regu-
lation by HU.44,45 In addition, HU through regulating spe-
cific miRNA levels,41,46 could differentially block or
unblock translation of the activator and repressor TF pro-
teins. During erythropoiesis, GATA-1 protein has been
shown to be post-transcriptionally phosphorylated and
subsequently degraded through the ubiquitin-proteasome
pathway.47-49 These HU-downstream pathways that regu-
late protein synthesis and stability of key TFs in the 
γ-globin promoter complex, as well as other γ-globin mod-
ulators such as lysine specific demethylase 1 (LSD1) and
GPC1 that could regulate γ-globin through pathways inde-
pendent of HU,13,50 may provide targets for designing new
SCD drugs to ameliorate the SCD symptoms of HU
low/non-responsive patients. 
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